Filing Details

Accession Number:
0001753926-25-001111
Form Type:
13G Filing
Publication Date:
2025-07-07 20:00:00
Filed By:
3i, LP
Company:
Pelthos Therapeutics Inc.
Filing Date:
2025-07-08
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
3i, LP 0 303,138 9.9%
3i Management LLC 0 303,138 9.9%
Maier Joshua Tarlow 0 303,138 9.9%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  As more fully described in Item 4 of this statement on Schedule 13G (this ''Schedule 13G''), such percentage is based on 3,034,416 shares of common stock, par value $0.0001 per share, of the issuer (the ''Common Stock'') outstanding, as verified with the issuer as of July 7, 2025, and does not give full effect to the shares of Common Stock issuable upon full conversion of the shares of Series A Convertible Preferred Stock, par value $0.0001 per share (the ''Preferred Stock''), directly held by the reporting person, which exercise is subject to a 9.99% beneficial ownership blocker (the ''Blocker''). Such numbers of shares of Common Stock reflect the issuer's 1-for-10 reverse stock split of its outstanding shares of Common Stock that was effected on July 1, 2025 (the ''Reverse Stock Split'').


SCHEDULE 13G



Comment for Type of Reporting Person:  As more fully described in Item 4 of this Schedule 13G, such percentage is based on 3,034,416 shares of Common Stock outstanding, as verified with the issuer as of July 7, 2025, and does not give full effect to the shares of Common Stock issuable upon full conversion of the shares of the Preferred Stock indirectly held by the reporting person, which exercise is subject to a Blocker. Such numbers of shares of Common Stock reflect the Reverse Stock Split.


SCHEDULE 13G



Comment for Type of Reporting Person:  As more fully described in Item 4 of this Schedule 13G, such percentage is based on 3,034,416 shares of Common Stock outstanding, as verified with the issuer as of July 7, 2025, and does not give full effect to the shares of Common Stock issuable upon full conversion of the shares of the Preferred Stock indirectly held by the reporting person, which exercise is subject to a Blocker. Such numbers of shares of Common Stock reflect the Reverse Stock Split.


SCHEDULE 13G


 
3i, LP
 
Signature:/s/ 3i, LP
Name/Title:Maier Joshua Tarlow, Manager of 3i Management LLC, General Partner of 3i, LP
Date:07/08/2025
 
3i Management LLC
 
Signature:/s/ 3i Management LLC
Name/Title:Maier Joshua Tarlow, Manager
Date:07/08/2025
 
Maier Joshua Tarlow
 
Signature:/s/ Maier Joshua Tarlow
Name/Title:Maier Joshua Tarlow
Date:07/08/2025